DOCSLIB.ORG

Journal 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Journal 2013 Journal of ENT masterclass ISSN 2047-959X Journal of ENT MASTERCLASS® Journal of Journal ENT MASTERCLASS ® www.entmasterclass.com VOL: 6 No: 1 Year Book 2013 Volume 6 Number 1 TriVantage | APS | NIM 3.0 Confidence Security Safety Also Available: AlsoGaviscon Available: Advance Peppermint GavisconSuspension Advance (sodium Peppermint alginate, potassium Suspensionhydrogen (sodiumcarbonate) alginate, and Gaviscon potassium hydrogenAdvance carbonate) Mint Chewable and GavisconTablets (sodium Advancealginate, Mintpotassium Chewable bicarbonate). Tablets (sodium alginate, potassium bicarbonate). ffoorr L LPPRR LPRadvice.co.uk LPSeeR howa it wdorkvs: LiPcRade.vice.cco.uok/d.emuo k See how it works: LPRadvice.co.uk/demo JOINT ESSENTIAL INFORMATION cases of congestive cardiac failure and renal impairment or when taking drugs which can increase JOINTGaviscon ESSENTIAL Advance INFORMATION Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed casesplasma of congestive potassium cardiaclevels. Eachfailure 10 and ml renalcontains impairment 200 mg (2.0or when mmol) taking of calcium drugs whichcarbonate. can increase This GavisconSuspension, Advance Gaviscon Peppermint Advance Flavour Mint Chewable Oral Suspension, Tablets. Gaviscon Advance Aniseed plasmamedicinal potassium product levels. contains Each Methyl 10 ml hydroxybenzoate contains 200 mg and (2.0 Propyl mmol) hydroxybenzoate, of calcium carbonate. which This may cause Suspension,Active substances Gaviscon Gaviscon Advance Advance Mint Chewable Peppermint Tablets. Flavour,Gaviscon Advance Aniseed Suspension: medicinalallergic reactionsproduct contains (possibly Methyl delayed). hydroxybenzoate Gaviscon Advance and Propyl Mint Chewable hydroxybenzoate, Tablets: which Each maytwo-tablet cause ActiveEach 5substances ml dose contains Gaviscon sodium Advance alginate Peppermint 500.0mg Flavour,Gaviscon and potassium hydrogenAdvance Aniseedcarbonate Suspension: 100.0mg allergicdose has reactions a sodium (possibly content delayed). of 103mg Gaviscon (4.5mmol) Advance and a Mint potassium Chewable content Tablets: of 78mg Each (2.0mmol). two-tablet This EachGaviscon 5 ml doseAdvance contains Mint sodiumChewable alginate Tablets: 500.0mg Sodium and alginate potassium 500 mg hydrogen and Potassium carbonate bicarbonate 100.0mg 100 doseshould has bea sodium taken into content account of 103mg when a(4.5mmol) highly restricted and a potassium salt diet is content recommended, of 78mg (2.0mmol).e.g. in some This cases Gavisconmg per tablet.Advance Indications: Mint Chewable Treatment Tablets: of symptomsSodium alginate resulting 500 from mg andthe refluxPotassium of acid, bicarbonate bile and pepsin100 shouldof congestive be taken cardiac into account failure when and renala highly impairment restricted or salt when diet taking is recommended, drugs which e.g.can inincrease some cases plasma mginto per the tablet. oesophagus Indications: such Treatmentas acid regurgitation, of symptoms heartburn, resulting indigestionfrom the reflux (occurring of acid, due bile to and the pepsinreflux of ofpotassium congestive levels. cardiac Each failure two-tablet and renal dose impairment contains 200or when mg (2.0taking mmol) drugs of whichcalcium can carbonate. increase plasma intostomach the oesophagus contents), suchfor instance, as acid regurgitation,after gastric surgery, heartburn, as aindigestion result of hiatus (occurring hernia, due during to the reflux of potassiumGaviscon levels.Advance Each Tablets two-tablet may cause dose containscentral nervous 200 mg system (2.0 mmol) depression of calcium in the carbonate. presence of renal stomachpregnancy, contents), accompanying for instance, reflux after oesophagitis, gastric surgery, including as a symptoms result of hiatus of laryngopharyngeal hernia, during reflux such Gavisconinsufficiency Advance and Tabletsshould maynot be cause used central in patients nervous with system renal failure. depression Due toin itsthe aspartame presence ofcontent renal this pregnancy,as hoarseness accompanying and other voicereflux disorders,oesophagitis, sore including throats and symptoms cough. Canof laryngopharyngeal also be used to treat reflux the such insufficiencyproduct should and notshould be givennot be to used patients in patients with phenylketonuria. with renal failure. Side-Effects: Due to its aspartameVery rarely content (<1/10,000) this assymptoms hoarseness of gastro-oesophagealand other voice disorders, reflux soreduring throats concomitant and cough. treatment Can also with be or used following to treat withdrawal the productpatients should may developnot be given allergic to patients manifestations with phenylketonuria. such as urticaria Side-Effects: or bronchospasm, Very rarely anaphylactic (<1/10,000) or symptomsof acid suppressing of gastro-oesophageal therapy. Dosage reflux Instructions:during concomitant Gaviscon treatment Advance with Peppermint or following Flavour withdrawal Oral patientsanaphylactoid may develop reactions. allergic manifestations such as urticaria or bronchospasm, anaphylactic or ofSuspension, acid suppressing Gaviscon therapy. Advance Dosage Aniseed Instructions: Suspension: Gaviscon Adults andAdvance children Peppermint 12 years Flavourand over: Oral 5-10 anaphylactoidNHS List Price: reactions. Gaviscon Advance Peppermint Flavour Oral Suspension: 250ml - £2.56, 500ml - Suspension,ml after meals Gaviscon and at Advance bedtime Aniseed (one to Suspension: two 5 ml measuring Adults and spoons). children Gaviscon 12 years Advance and over: Mint 5-10 NHS£5.12 List Gaviscon Price: Gaviscon Advance Advance Aniseed PeppermintSuspension: Flavour 250ml Oral- £2.56, Suspension: 500ml - 250ml£5.12 Gaviscon- £2.56, 500mlAdvance - mlChewable after meals Tablets: and atFor bedtime oral administration (one to two after5 ml measuringbeing thoroughly spoons). chewed. Gaviscon Adults Advance and children Mint 12 £5.12Mint GavisconChewable Advance Tablets: Aniseed 60 Tablets Suspension: - £3.07 Marketing250ml - £2.56, Authorisation: 500ml - £5.12 Gaviscon Gaviscon Advance Advance Chewableyears and Tablets: over: One For tooral two administration tablets after aftermeals being and thoroughly at bedtime. chewed. Children Adults under and 12 children years: 12Should MintPeppermint Chewable Flavour Tablets: Oral 60 Suspension- Tablets - £3.07 PL 00063/0612Marketing Authorisation: Gaviscon Advance Gaviscon Aniseed Advance Suspension - PL yearsbe given and over:only on One medical to two advice. tablets Elderly: after meals No dose and modification at bedtime. is Children required under for this 12 age years: group Should Peppermint00063/0108. Flavour Gaviscon Oral Suspension- Advance Mint PL Chewable 00063/0612 Tablets Gaviscon – PL 00063/613 Advance Aniseed Supply Suspension Classification - PL be given only on medical advice. Elderly: No dose modification is required for this age group 00063/0108. Gaviscon Advance Mint Chewable Tablets – PL 00063/613 Supply Classification Contraindications: Hypersensitivity to any of the ingredients, including the esters of Gaviscon Advance Peppermint Flavour Oral Suspension/ Gaviscon Advance Aniseed Suspension - P Contraindications:hydroxybenzoates (parabens).Hypersensitivity Precautions to any of andthe ingredients,Warnings: Care including needs the to estersbe taken of in treating GavisconGaviscon Advance Advance Peppermint Mint Chewable Flavour Tablets Oral Suspension/- GSL Marketimng Gaviscon authorisation Advance Aniseed Holder: Suspension Reckitt - P hydroxybenzoatespatients with hypercalcaemia, (parabens). Precautions nephrocalcinosis and Warnings: and recurrent Care calcium needs tocontaining be taken renalin treating calculi. GavisconBenckiser Advance Healthcare Mint (UK)Chewable Limited, Tablets Dansom - GSL Lane, Marketimng Hull, HU8 7DS.authorisation Holder: Reckitt patientsThere is with a possibility hypercalcaemia, of reduced nephrocalcinosis efficacy in patients and recurrent with very calcium low levels containing of gastric renal acid.Treatment calculi. of BenckiserGaviscon Healthcare and the sword (UK) andLimited, circle Dansom symbol Lane,are trade Hull, marks. HU8 7DS. Therechildren is a youngerpossibility than of reduced12 years efficacy of age is in not patients generally with recommended, very low levels exceptof gastric on medicalacid.Treatment advice.If of Gaviscon and the sword and circle symbol are trade marks. children younger than 12 years of age is not generally recommended, except on medical advice.If Adverse events should be reported. Reporting forms and information can be symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon Adverse events should be reported. Reporting forms and information can be UC201403300EE symptoms do not improve after seven days, the clinical situation should be reviewed. Gaviscon found at www.yellowcard.gov.uk/yellowcard Adverse events should also be reported Innovating for life. Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Each 10 ml found at www.yellowcard.gov.uk/yellowcard Adverse events should also be reported Advance Peppermint Flavour Oral Suspension, Gaviscon Advance Aniseed Suspension: Each 10 ml to Reckitt Benckiser on 0500 455 456. dose has a sodium content of 106 mg (4.6mmol) and a potassium content of 78 mg (2.0 mmol). to Reckitt Benckiser on 0500 455 456. doseThis has should a sodium be taken content into accountof 106 mg when (4.6mmol) a highly and restricted a potassium salt diet content is recommended, of 78 mg (2.0 e.g. mmol). in some Date
Load more

Recommended publications
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Diseases of Salivary Glands: Review
    ISSN: 1812–1217 Diseases of Salivary Glands: Review Alhan D Al-Moula Department of Dental Basic Science BDS, MSc (Assist Lect) College of Dentistry, University of Mosul اخلﻻضة امخجوًف امفموي تُئة رطبة، حتخوي ػىل طبلة ركِلة من امسائل ثدغى انوؼاب ثغطي امسطوح ادلاخوَة و متﻷ امفراغات تني ااطَة امفموًة و اﻷس نان. انوؼاب سائل مؼلد، ًنذج من امغدد انوؼاتَة، اذلي ًوؼة دورا" ىاما" يف اﶈافظة ػىل سﻻمة امفم. املرىض اذلٍن ؼًاهون من هلص يف اﻷفراز انوؼايب حكون دلهيم مشبلك يف اﻷلك، امخحدث، و امبوع و ًطبحون غرضة مﻷههتاابت يف اﻷغش َة ااطَة و امنخر املندرش يف اﻷس نان. ًوخد ثﻻثة أزواج من امغدد انوؼاتَة ام ئرُسة – امغدة امنكفِة، امغدة حتت امفكِة، و حتت انوساهَة، موضؼيا ٍكون خارج امخجوًف امفموي، يف حمفظة و ميخد هظاهما املنَوي مَفرغ افرازاهتا. وًوخد أًضا" امؼدًد من امغدد انوؼاتَة امطغرية ، انوساهَة، اتحنكِة، ادلىوزيًة، انوساهَة احلنكِة وما كبل امرخوًة، ٍكون موضؼيا مﻷسفل و مضن امغشاء ااطي، غري حماطة مبحفظة مع هجاز كنَوي كطري. افرازات امغدد انوؼاتَة ام ئرُسة مُست مدشاهبة. امغدة امفكِة ثفرز مؼاب مطيل غين ابﻷمِﻻز، وامغدة حتت امفكِة ثنذج مؼاب غين اباط، أما امغدة حتت انوساهَة ثنذج مؼااب" مزخا". ثبؼا" ميذه اﻷخذﻻفات، انوؼاب املوحود يق امفم ٌشار امَو مكزجي. ح كرَة املزجي انوؼايب مُس ثس َطا" واملادة اﻷضافِة اموػة من لك املفرزات انوؼاتَة، اكمؼدًد من امربوثُنات ثنذلل ثرسػة وثوخطق هبدروكس َل اﻷتُذاًت مﻷس نان و سطوح ااطَة امفموًة. ثبدأ أمراض امغدد انوؼاتَة ػادة تخغريات اندرة يف املفرزات و ام كرتَة، وىذه امخغريات ثؤثر اثهواي" من خﻻل جشلك انووحية اجلرثومِة و املوح، اميت تدورىا ثؤدي اىل خنور مذفش َة وأمراض وس َج دامعة. ىذه اﻷمراض ميكن أن ثطبح شدًدة تؼد املؼاجلة امشؼاغَة ﻷن امؼدًد من احلاﻻت اجليازًة )مثل امسكري، امخوَف اهكُيس( ثؤثر يف اجلراين انوؼايب، و ٌش خيك املرض من حفاف يف امفم.
    [Show full text]
  • Applications of Microfluidic Chips in Optical Manipulation Photoporation
    APPLICATIONS OF MICROFLUIDIC CHIPS IN OPTICAL MANIPULATION & PHOTOPORATION Robert Frank Marchington A Thesis Submitted for the Degree of PhD at the University of St. Andrews 2010 Full metadata for this item is available in Research@StAndrews:FullText at: https://research-repository.st-andrews.ac.uk/ Please use this identifier to cite or link to this item: http://hdl.handle.net/10023/1633 This item is protected by original copyright Applications of Microfluidic Chips in Optical Manipulation & Photoporation Robert Frank Marchington A thesis presented for the degree of Doctor of Philosophy Optical Trapping & Microphotonics Groups School of Physics & Astronomy University of St Andrews June 2010 Dedicated to Mum & Mike Joe & Xanthoula Applications of Microfluidic Chips in Optical Manipulation and Photoporation Robert Frank Marchington Submitted for the degree of Doctor of Philosophy June 2010 Abstract Integration and miniaturisation in electronics has undoubtedly revolutionised the modern world. In biotechnology, emerging lab-on-a-chip (LOC) methodologies pro- mise all-integrated laboratory processes, to perform complete biochemical or medical synthesis and analysis encapsulated on small microchips. The integration of electri- cal, optical and physical sensors, and control devices, with fluid handling, is creating a new class of functional chip-based systems. Scaled down onto a chip, reagent and sample consumption is reduced, point-of-care or in-the-field usage is enabled through portability, costs are reduced, automation increases the ease of use, and favourable scaling laws can be exploited, such as improved fluid control. The capacity to mani- pulate single cells on-chip has applications across the life sciences, in biotechnology, pharmacology, medical diagnostics and drug discovery.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Classification of Salivary Gland Disorders
    Salivary Gland Diseases and Disorders Dr. Mahmoud E. Khalifa Prof of OMFS Lecture ILOs At the end of this chapter you should be able to: 1. Distinguish the clinical features of infections of the salivary glands from those in other structures 2. Differentiate on clinical grounds between infection, obstruction, benign and malignant neoplasms of the salivary glands 3. Plan and evaluate the results of the investigation of disorders of the salivary glands 4. List the important/relevant information to be elicited from patients with salivary gland disorders 5. Select cases which require referral for a specialist opinion 6. Describe the causes of a dry mouth and be able to distinguish between organic and functional causes. Anatomy Major glands Minor glands 3 pairs Situated mostly 800 to 1000 in the oral cavity Parotid Submandibular The majority atAlso found in the the junction of pharynx, larynx, the hard and soft trachea, and palates sinuses sublingual Functions These glands function to produce saliva, which serves as Lubricant for speech & swallowing Assists taste Immunologic (antibacterial) Digestive Cleansing properties Based on the type of secretion, the salivary glands may be grouped as: (i) Serous, (ii) Mucous and (iii) Mixed. Parotid gland secretion is serous in nature. The sublingual gland secretes mixed, but predominantly mucous. The submandibular gland secretion is also mixed, but is predominantly serous. The minor glands secrete mucous saliva. Parotid Gland The parotid gland is the largest salivary gland, the secretion of which is serous in nature. It is pyramidal in shape; The base located superficial and apex medially The base is triangular in shape its apex is towards the angle of the mandible, the base at the external acoustic meatus The parotid duct (Stenson‘s duct) Emerges at the anterior part of the gland.
    [Show full text]
  • Chapter 11. Non-Neoplastic Diseases of Salivary Glands
    Surgical pathology of the mouth and jaws R. A. Cawson, J. D. Langdon, J. W. Eveson 11. Non-neoplastic diseases of salivary glands Investigation Investigations will be discussed in relation to specific disorders and those more appropriate to neoplasms are discussed in the following chapter. However, it must be emphasized that chronic inflammatory swellings of the major salivary glands, in particular, sometimes cannot be distinguished from neoplasms clinically. Nevertheless, biopsy of the parotid glands is contraindicated because of the frequency of pleomorphic adenomas which can be seeded into the surrounding tissues to produce multiple recurrences. There are also the risks of damaing branches of the facial nerve or of producing a parotid fistula. For imaging techniques, see Chapters 1 and 12. Developmental disorders Aplasia/agenesis. Complete absence of one or more salivary glands is very rare, but occasionally the parotid glands are absent. Absence of all major salivary glands is even more rare. Duct atresia. This is also rare, but usually affects the submandibular duct in the floor of the mouth. Absence of the duct results in retention cysts of the submandibular and sublingual glands. Salivary gland hypoplasia. This can be a feature of the Melkersson-Rosenthal syndrome. The hypoplasia possibly may be secondary to atrophy of parasympathetic nerves thought to be implicated in this syndrome. Congenital salivary fistulae. These are sometimes seen in association with branchial clefts. Aberrant salivary tissue. This is common in the cervical lymph nodes (where it should not be mistaken for a metastasis) and may be found in the middle ear cleft. Stafne's bone cavity is another example.
    [Show full text]
  • Molecular Cloning: a Laboratory Manual, 4Th Edition
    This is a free sample of content from Molecular Cloning: A Laboratory Manual, 4th edition. Click here for more information or to buy the book. VOLUME 1 Molecular Cloning A LABORATORY MANUAL FOURTH EDITION © 2012 by Cold Spring Harbor Laboratory Press This is a free sample of content from Molecular Cloning: A Laboratory Manual, 4th edition. Click here for more information or to buy the book. OTHER TITLES FROM CSHL PRESS LABORATORY MANUALS Antibodies: A Laboratory Manual Imaging: A Laboratory Manual Live Cell Imaging: A Laboratory Manual, 2nd Edition Manipulating the Mouse Embryo: A Laboratory Manual, 3rd Edition RNA: A Laboratory Manual HANDBOOKS Lab Math: A Handbook of Measurements, Calculations, and Other Quantitative Skills for Use at the Bench Lab Ref, Volume 1: A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench Lab Ref, Volume 2: A Handbook of Recipes, Reagents, and Other Reference Tools for Use at the Bench Statistics at the Bench: A Step-by-Step Handbook for Biologists WEBSITES Molecular Cloning, A Laboratory Manual, 4th Edition, www.molecularcloning.org Cold Spring Harbor Protocols, www.cshprotocols.org © 2012 by Cold Spring Harbor Laboratory Press This is a free sample of content from Molecular Cloning: A Laboratory Manual, 4th edition. Click here for more information or to buy the book. VOLUME 1 Molecular Cloning A LABORATORY MANUAL FOURTH EDITION Michael R. Green Howard Hughes Medical Institute Programs in Gene Function and Expression and in Molecular Medicine University of Massachusetts Medical School Joseph Sambrook Peter MacCallum Cancer Centre and the Peter MacCallum Department of Oncology The University of Melbourne, Australia COLD SPRING HARBOR LABORATORY PRESS Cold Spring Harbor, New York † www.cshlpress.org © 2012 by Cold Spring Harbor Laboratory Press This is a free sample of content from Molecular Cloning: A Laboratory Manual, 4th edition.
    [Show full text]
  • Treatments for Ankyloglossia and Ankyloglossia with Concomitant Lip-Tie Comparative Effectiveness Review Number 149
    Comparative Effectiveness Review Number 149 Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie Comparative Effectiveness Review Number 149 Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2012-00009-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, TN Investigators: David O. Francis, M.D., M.S. Sivakumar Chinnadurai, M.D., M.P.H. Anna Morad, M.D. Richard A. Epstein, Ph.D., M.P.H. Sahar Kohanim, M.D. Shanthi Krishnaswami, M.B.B.S., M.P.H. Nila A. Sathe, M.A., M.L.I.S. Melissa L. McPheeters, Ph.D., M.P.H. AHRQ Publication No. 15-EHC011-EF May 2015 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2012-00009-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Plastic Surgery Essentials for Students Handbook to All Third Year Medical Students Concerned with the Effect of the Outcome on the Entire Patient
    AMERICAN SOCIETY OF PLASTIC SURGEONS YOUNG PLASTIC SURGEONS STEERING COMMITTEE Lynn Jeffers, MD, Chair C. Bob Basu, MD, Vice Chair Eighth Edition 2012 Essentials for Students Workgroup Lynn Jeffers, MD Adam Ravin, MD Sami Khan, MD Chad Tattini, MD Patrick Garvey, MD Hatem Abou-Sayed, MD Raman Mahabir, MD Alexander Spiess, MD Howard Wang, MD Robert Whitfield, MD Andrew Chen, MD Anureet Bajaj, MD Chris Zochowski, MD UNDERGRADUATE EDUCATION COMMITTEE OF THE PLASTIC SURGERY EDUCATIONAL FOUNDATION First Edition 1979 Ruedi P. Gingrass, MD, Chairman Martin C. Robson, MD Lewis W.Thompson, MD John E.Woods, MD Elvin G. Zook, MD Copyright © 2012 by the American Society of Plastic Surgeons 444 East Algonquin Road Arlington Heights, IL 60005 All rights reserved. Printed in the United States of America ISBN 978-0-9859672-0-8 i INTRODUCTION PREFACE This book has been written primarily for medical students, with constant attention to the thought, A CAREER IN PLASTIC SURGERY “Is this something a student should know when he or she finishes medical school?” It is not designed to be a comprehensive text, but rather an outline that can be read in the limited time Originally derived from the Greek “plastikos” meaning to mold and reshape, plastic surgery is a available in a burgeoning curriculum. It is designed to be read from beginning to end. Plastic specialty which adapts surgical principles and thought processes to the unique needs of each surgery had its beginning thousands of years ago, when clever surgeons in India reconstructed individual patient by remolding, reshaping and manipulating bone, cartilage and all soft tissues.
    [Show full text]
  • Clinical and Molecular Investigation of Rare
    CLINICAL AND MOLECULAR INVESTIGATION OF RARE CONGENITAL DEFECTS OF THE PALATE RIMANTE SESELGYTE A thesis submitted for the degree of Doctor of Philosophy to University College London August 2019 page Title 1 DECLARATION I, Rimante Seselgyte, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed……………………….. Declaration 3 ABSTRACT Cleft palate (CP) affects around 1/1500 live births and, along with cleft lip, is one of the most common forms of birth defect. The studies presented here focus on unusual defects of the palate, especially to understand better the rarely reported but surprisingly common condition called submucous cleft palate (SMCP). The frequency and consequences of SMCP from a surgical perspective were first investigated based on the caseload of the North Thames Cleft Service at Great Ormond Street Hospital and St Andrew's Centre, Broomfield Hospital, Mid Essex Hospitals Trust. It was previously reported that up to 80% of individuals with unrepaired SMCP experience speech difficulties as a consequence of velopharyngeal insufficiency (VPI). Attempted repair of the palatal defect can sometimes give poor results, so controversies still exist about the correct choice of surgical technique to use. Over 23 years, 222 patients at The North Thames Cleft Service underwent operations to manage SMCP. Nearly half of them (42.8%) were diagnosed with 22q11.2 deletion syndrome (22q11.2 DS). The first operation was palate repair, with an exception of one case, followed by a second surgical intervention required in approximately half of the patients.
    [Show full text]
  • Dental Manifestations in Bariatric Patients – Review of Literature
    www.scielo.br/jaos Dental manifestations in bariatric patients – review of literature Carolina Silveira BARBOSA1, Gabriel Salles BARBÉRIO1, Vinicius Rizzo MARQUES1, Vitor de Oliveira BALDO1, Marília Afonso Rabelo BUZALAF2, Ana Carolina MAGALHÃES3 1- Undergraduate student, Bauru School of Dentistry, University of São Paulo. 2- DDS, MSc, PhD, Full Professor, Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo. 3- DDS, MSc, PhD, Assistant Professor, Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo. Corresponding address: Ana Carolina Magalhães - Faculdade de Odontologia de Bauru - Universidade de São Paulo - Departamento de Ciências Biológicas - Al. Octávio Pinheiro Brisolla, 9-75 Bauru-SP 17012-901 (Brazil) - Phone: + 55 14 32358246 Fax: + 55 14 32343164 - e-mail: [email protected] Received: August 19, 2009 - Accepted: February 19, 2010 ABSTRACT he rate of bariatric surgery has significantly risen in the past decade as an increasing Tprevalence of extreme obesity can be observed. Although bariatric surgery is an effective therapeutic modality for extreme obesity, it is associated with risk factors affecting also oral health. Based on an overview of the current literature, this paper presents a summary of dental manifestations in bariatric patients. Bariatric surgeries are associated with an increased risk for gastro-esophageal reflux which in turn might account for the higher amount of carious and erosive lesions observed in bariatric patients. As a result, also dentin hypersensitivity might be observed more frequently. The current data indicate that recommended postsurgical meal patterns and gastric reflux might increase the risk for dental lesions, particularly in the presence of other risk factors, such as consumption of sweet-tasting foods and acidic beverages.
    [Show full text]
  • Salivary Gland Pathology 25.Pdf
    k Index 461 Mechanoreceptors, 15 patient history, 284 Melanoma pleomorphic adenoma, 286–290 desmoplastic subtype, 63 polymorphous low-grade adenocarcinoma, 174–175, 306, histopathology, 381 309, 312 lower lip, 380–381 primary lymphomas, 368 metastases, 62–63, 189 radiation therapy, 328 nodular, 379 sites of, 285 Merkel cell tumors, metastases, 62, 63, 375 staging, 193–196 Mesenchymal-epithelial transition (MET), 214 Mixed tumor. See Pleomorphic adenoma(s) Mesenchymal neoplasms, 188 Modified Blair incision, 238, 239 Mesenchymal salivary gland tumors Monomorphic adenoma, 167–169, 290 lymphatic malformations, 398, 400 Monomorphic clear cell tumor, 182 neural tumors, 398, 401, 402 Motion artifacts, 21–22 vascular tumors, 397–398, 397–399 Mouth Messenger ribonucleic acid (mRNA), 208, 209, 209 dry, 141 Metal deposits, brain, 24 ranula, 98, 99, 100 Metallic implants, 21, 22 MRI. See Magnetic resonance imaging (MRI) Metalloproteinases, 142 MRS. See Magnetic resonance spectroscopy (MRS) Metastases, 189 Mucocele, 97, 99, 114, 412 diagnostic imaging, 62–64, 63 Mucoepidermoid carcinoma (MEC), 170–172, 214, 389, distant. See Distant metastases 390, 396, 404 regional. See Regional metastases ADC values, 27 skip, 270 biomarkers, 190, 263 Metastasizing mixed tumor, 182, 289 buccal mucosa, 294 Metastasizing pleomorphic adenoma, 287 children, 297 Methicillin resistant S. aureus (MRSA), acute bacterial clear cell variant, 383 parotitis, 75, 78, 96 diagnostic imaging, 56, 57 k Microliths, 439 fixed to mandible, 277 k Middle ear, aberrant glands, 438 grading,
    [Show full text]